Voyager Therapeutics, Inc. $VYGR Shares Purchased by Patriot Financial Group Insurance Agency LLC

Patriot Financial Group Insurance Agency LLC increased its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 10.0% in the second quarter, HoldingsChannel reports. The firm owned 121,098 shares of the company’s stock after acquiring an additional 11,000 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in Voyager Therapeutics were worth $377,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of VYGR. Wellington Management Group LLP lifted its holdings in shares of Voyager Therapeutics by 13.9% during the fourth quarter. Wellington Management Group LLP now owns 261,251 shares of the company’s stock worth $1,481,000 after purchasing an additional 31,882 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Voyager Therapeutics by 53.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company’s stock worth $204,000 after purchasing an additional 21,149 shares during the period. CWM LLC lifted its holdings in shares of Voyager Therapeutics by 856.3% during the first quarter. CWM LLC now owns 10,471 shares of the company’s stock worth $35,000 after purchasing an additional 9,376 shares during the period. Privium Fund Management B.V. purchased a new position in Voyager Therapeutics during the first quarter valued at approximately $73,000. Finally, Invesco Ltd. lifted its holdings in Voyager Therapeutics by 100.8% in the first quarter. Invesco Ltd. now owns 48,540 shares of the company’s stock valued at $164,000 after acquiring an additional 24,368 shares during the period. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Stock Performance

NASDAQ VYGR opened at $4.86 on Friday. The business has a fifty day moving average price of $3.81 and a 200 day moving average price of $3.45. Voyager Therapeutics, Inc. has a one year low of $2.64 and a one year high of $8.27. The company has a market cap of $269.58 million, a P/E ratio of -2.63 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. The firm had revenue of $5.20 million during the quarter, compared to analyst estimates of $9.50 million. As a group, sell-side analysts predict that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on VYGR shares. Weiss Ratings reissued a “sell (d)” rating on shares of Voyager Therapeutics in a report on Saturday, September 27th. Wedbush decreased their price target on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a report on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.25.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.